hero section gradient
14 handpicked stocks

SRT Revival: Performance Parts

Stellantis is bringing back its legendary SRT performance division, creating exciting opportunities throughout the automotive supply chain. This collection features carefully selected stocks of parts makers and retailers positioned to benefit from this high-performance resurgence.

Author avatar

Han Tan | Market Analyst

Published on July 3

Your Basket's Financial Footprint

Aggregate and breakdown of market capitalisation for the SRT Revival: Performance Parts basket.

Key Takeaways for Investors:
  • Large‑cap dominance tends to lower volatility, offering more stable, broad-market-like returns rather than speculative swings.
  • Treat this basket as a core holding for diversification, not a speculative allocation for high-risk trading.
  • Expect steady, long‑term capital appreciation rather than rapid, short‑term gains; growth likely moderate and measured.
Total Market Cap
  • GTX: $2.52B

  • BWA: $9.48B

  • MOD: $8.23B

  • Other

About This Group of Stocks

1

Our Expert Thinking

This theme captures the ripple effect of Stellantis reviving its Street and Racing Technology division. As new high-performance vehicles enter development, the companies supplying everything from turbochargers to specialized electronics are positioned for potential growth in both OEM supply and aftermarket sales.

2

What You Need to Know

This is a tactical, event-driven investment opportunity within the automotive sector. These stocks represent various segments of the performance parts ecosystem, including direct suppliers to Stellantis and aftermarket distributors who may benefit as the SRT enthusiast market expands.

3

Why These Stocks

Each company was selected based on its strategic position within the performance automotive supply chain. From manufacturing critical components like turbochargers and suspension systems to distributing specialized parts, these businesses are directly aligned with SRT's revival.

Why You'll Want to Watch These Stocks

🏎️

Riding the Performance Wave

The revival of Stellantis' legendary SRT division signals a significant investment in high-performance vehicles that could create years of demand for specialized parts and components.

⚙️

Supply Chain Winners

From turbochargers to digital cockpits, these companies represent the critical suppliers who stand to win lucrative contracts as new SRT models enter development across Dodge, Jeep, and Ram brands.

💨

First-Mover Advantage

This collection gives you early exposure to a strategic shift in the automotive industry before the full market impact of SRT's revival is widely recognized and priced into these stocks.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Global Infrastructure Partners: UAE Exposure Risks

Global Infrastructure Partners: UAE Exposure Risks

The UAE's strategic push for economic diversification and smart city development is creating significant demand for advanced construction and infrastructure solutions. This basket provides exposure to a selection of US and EU-listed companies that supply essential materials, technology, and engineering services to the region's projects.

UAE Infrastructure Global Suppliers Breakdown

UAE Infrastructure Global Suppliers Breakdown

As the UAE continues its ambitious economic diversification, demand for world-class infrastructure creates opportunities for the companies that build it. This basket offers exposure to US and EU-listed industrial, materials, and technology firms that are integral to developing these large-scale projects.

Antiviral M&A Wave: Biotech Opportunities in 2025

Antiviral M&A Wave: Biotech Opportunities in 2025

Merck's $9.2 billion acquisition of Cidara Therapeutics strengthens its antiviral pipeline as a key patent nears expiry. This major deal signals a growing trend of pharmaceutical giants buying smaller biotechs, creating potential opportunities among companies with promising infectious disease therapies.

Frequently Asked Questions